ClinicalTrials.gg
WithdrawnNCT03417037Updated Apr 30, 2018

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

A Phase 3 interventional study of BMS-986205 and Nivolumab in Lung Cancer and Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 83 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-30.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

How we know · 9 judgments

Why this study was withdrawn
Business objectives have changed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Enrollment
104th of 107
0 · median 169
Started
2018
with 3 others
Phase 3
27 of 131
5 open now
Registered
66th of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 104th largest by enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2018, is one of 27 in phase 3, and was the 66th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

03

Conditions studied

  • Lung Cancer
  • Non-Small Cell Lung Cancer

Browse trials for

04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • confirmed stage IV NSCLC per the 8th IASLC of squamous or nonsquamous histology
  • Locally advanced disease with recurrence after chemoradiation therapy (stage IIIB disease, specifically refers to patients with no curative treatment options)
  • No prior systemic anti-cancer therapy (including EGFR and ALK/ROS1 inhibitors) given as primary therapy for advanced or disease
  • Participants must have biomarker test results available for randomization
  • Performance Status of ≤ 1
  • by CT or MRI per 1.1 criteria

Exclusion criteria

Exclusion Criteria:

  • Participants with known sensitizing EGFR mutations or known ALK/ROS1 rearrangements
  • Participants with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Participants with an active, known or suspected disease [Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll]
  • Participants with untreated are excluded [Participants are eligible if CNS metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to first treatment]

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A

    BMS-986205 and Nivolumab administered in combination

    Drug: BMS-986205 · Biological: Nivolumab

  • Experimental
    Arm B

    BMS-986205 and Nivolumab administered in combination with chemotherapy

    Drug: BMS-986205 · Biological: Nivolumab · Drug: Chemotherapy

  • Active comparator
    Arm C

    Chemotherapy administered alone

    Drug: Chemotherapy

Interventions

  • DrugLinrodostatStudies of LinrodostatLinrodostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered orally daily, 100 mg

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • DrugChemotherapy

    Platinum-based doublet chemotherapy

07

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) measured by number of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group

    Time frame: 24 months

  2. Progression free survival (PFS) measured by the time between the date of randomization and the first date of documented progression, as determined by the Blinded Independent Central Review, or death, due to any cause, whichever occurs first

    Time frame: 34 months

Secondary outcomes

  1. Overall survival (OS) measured by the time between the date of randomization and the date of death due to any cause

    Time frame: Approximately 5 years

  2. Number of treatment-related adverse events (AE)

    Time frame: Approximately 5 years

  3. Number of treatment-related serious adverse events

    Time frame: Approximately 5 years

08

Study locations

83 sites
  • Local Institution
    San Diego, California 92123, United States
  • Local Institution
    Fort Myers, Florida 33916, United States
  • Local Institution
    Jacksonville, Florida 32256, United States
  • Local Institution
    Saint Petersburg, Florida 33705, United States
  • Local Institution
    Tallahassee, Florida 32308, United States
  • Local Institution
    West Palm Beach, Florida 33401, United States
  • Local Institution
    Decatur, Georgia 30033, United States
  • Local Institution
    Marietta, Georgia 30060, United States
  • Local Institution
    Wichita, Kansas 67214, United States
  • Local Institution
    Louisville, Kentucky 40202, United States
  • Local Institution
    Boston, Massachusetts 02114, United States
  • Local Institution
    Bridgeton, Missouri 63044, United States
  • Local Institution
    Lincoln, Nebraska 68510, United States
  • Local Institution
    Cleveland, Ohio 44106, United States
  • Local Institution
    Gettysburg, Pennsylvania 17325, United States
  • Local Institution
    Greenville, South Carolina 29607, United States
  • Local Institution
    Lebanon, Tennessee 37087, United States
  • Local Institution
    Fort Worth, Texas 76104, United States
  • Local Institution
    Lubbock, Texas 79430-0002, United States
  • Local Institution
    Darlinghurst, New South Wales 2010, Australia
  • Local Institution
    Brisbane, Queensland 4102, Australia
  • Local Institution
    Melbourne, Victoria 3004, Australia
  • Local Institution
    Murdoch, Western Australia 6150, Australia
  • Local Institution
    North Tamworth, 2340, Australia
  • Local Institution
    Vienna, 1090, Austria
  • Local Institution
    Wels, 4600, Austria
  • Local Institution
    Ipatinga, Minas Gerais 35160-158, Brazil
  • Local Institution
    Jd. Petropolis-Londrina, Parana 86015-520, Brazil
  • Local Institution
    Centro-porto Alegre, RIO Grande DO SUL 90050-170, Brazil
  • Local Institution
    Ijui, RIO Grande DO SUL 98700-000, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90610-000, Brazil
  • Local Institution
    Barretos, SAO Paulo 14780-070, Brazil
  • Local Institution
    Morumbi, SAO Paulo 05652-900, Brazil
  • Local Institution
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution
    Quebec, G1R 2J6, Canada
  • Local Institution
    Praha 2, 128 08, Czechia
  • Local Institution
    Besancon, 25030, France
  • Local Institution
    La Tronche, 38700, France
  • Local Institution
    Paris Cedex 5, 75248, France
  • Local Institution
    Pessac cedex, 33604, France
  • Local Institution
    Pringy Cedex, 74374, France
  • Local Institution
    Rennes Cedex 9, 35033, France
  • Local Institution
    Saint Herblain, 44805, France
  • Local Institution
    Toulon, 83000, France
  • Local Institution
    Berlin, 14165, Germany
  • Local Institution
    Gauting, 82131, Germany
  • Local Institution
    Gera, 07548, Germany
  • Local Institution
    Gottingen, 37075, Germany
  • Local Institution
    Grosshansdorf, 22927, Germany
  • Local Institution
    Hamburg, 21075, Germany
  • Local Institution
    Heidelberg, 69126, Germany
  • Local Institution
    Oldenburg, 26121, Germany
  • Local Institution
    Paderborn, 33098, Germany
  • Local Institution
    Wiesbaden, 65199, Germany
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Athens, 18547, Greece
  • Local Institution
    Thessaloniki, 54 622, Greece
  • Local Institution
    Modena, 41100, Italy
  • Local Institution
    Monza (MB), 20900, Italy
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Perugia, 06132, Italy
  • Local Institution
    Ravenna, 48121, Italy
  • Local Institution
    Reggio Emilia, 42100, Italy
  • Local Institution
    Fukushima-shi, Fukushima 9601295, Japan
  • Local Institution
    Morioka-shi, Iwate 0208505, Japan
  • Local Institution
    Osaka-sayama-shi, Osaka 5898511, Japan
  • Local Institution
    Kitaadachi-gun, Saitama 362-0806, Japan
  • Local Institution
    Seoul, 03080, Korea, Republic of
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Merida, Yucatan 97070, Mexico
  • Local Institution
    A Coruna, Galicia 15006, Spain
  • Local Institution
    Barcelona, 08035, Spain
  • Local Institution
    Madrid, 28041, Spain
  • Local Institution
    Majadahonda - Madrid, 28222, Spain
  • Local Institution
    Malaga, 29010, Spain
  • Local Institution
    Valencia, 46026, Spain
  • Local Institution
    Basel, 4031, Switzerland
  • Local Institution
    Taipei, 11217, Taiwan
  • Local Institution
    Taipei, Taiwan
  • Local Institution
    ?stanbul, 34890, Turkey
  • Local Institution
    Adana, 01250, Turkey
  • Local Institution
    Antalya, 07070, Turkey
  • Local Institution
    Istanbul, 34098, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2018; primary completion for Apr 2021, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Jan 31, 2018
StartEst.
May 24, 2018
Primary completionEst.
Apr 25, 2021
CompletionEst.
Aug 20, 2025
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03417037
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
May 24, 2018 (estimated)
Primary completion
Apr 25, 2021 (estimated)
Completion
Aug 20, 2025 (estimated)
Last update
Apr 30, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linrodostat

Start the discussion